ES2991947T3 - Uso de cannabidiol además de lamotrigina para el tratamiento de las convulsiones asociadas al síndrome de Lennox-Gastaut - Google Patents

Uso de cannabidiol además de lamotrigina para el tratamiento de las convulsiones asociadas al síndrome de Lennox-Gastaut Download PDF

Info

Publication number
ES2991947T3
ES2991947T3 ES18808075T ES18808075T ES2991947T3 ES 2991947 T3 ES2991947 T3 ES 2991947T3 ES 18808075 T ES18808075 T ES 18808075T ES 18808075 T ES18808075 T ES 18808075T ES 2991947 T3 ES2991947 T3 ES 2991947T3
Authority
ES
Spain
Prior art keywords
cbd
treatment
seizures
patients
cannabidiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18808075T
Other languages
English (en)
Spanish (es)
Inventor
Geoffrey Guy
Volker Knappertz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Research UK Ltd
Original Assignee
Jazz Pharmaceuticals Research UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60788456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2991947(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Research UK Ltd filed Critical Jazz Pharmaceuticals Research UK Ltd
Application granted granted Critical
Publication of ES2991947T3 publication Critical patent/ES2991947T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ES18808075T 2017-11-15 2018-11-15 Uso de cannabidiol además de lamotrigina para el tratamiento de las convulsiones asociadas al síndrome de Lennox-Gastaut Active ES2991947T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1718862.4A GB2568471B (en) 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy
PCT/GB2018/053315 WO2019097238A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome

Publications (1)

Publication Number Publication Date
ES2991947T3 true ES2991947T3 (es) 2024-12-05

Family

ID=60788456

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18808075T Active ES2991947T3 (es) 2017-11-15 2018-11-15 Uso de cannabidiol además de lamotrigina para el tratamiento de las convulsiones asociadas al síndrome de Lennox-Gastaut

Country Status (16)

Country Link
US (1) US20210169824A1 (https=)
EP (2) EP4487860A3 (https=)
JP (2) JP7391019B2 (https=)
KR (1) KR102786614B1 (https=)
CN (1) CN111629756A (https=)
AU (2) AU2018366443A1 (https=)
BR (1) BR112020009508A2 (https=)
CA (1) CA3082433A1 (https=)
DK (1) DK3710058T3 (https=)
ES (1) ES2991947T3 (https=)
FI (1) FI3710058T3 (https=)
GB (1) GB2568471B (https=)
IL (1) IL274633A (https=)
MX (2) MX2020005147A (https=)
RU (1) RU2020119390A (https=)
WO (1) WO2019097238A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
KR102891881B1 (ko) 2020-07-16 2025-11-26 주식회사 엘지에너지솔루션 듀얼 슬롯 다이 코터
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597280A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
WO2023060024A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US12544389B2 (en) * 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
WO2019097238A1 (en) 2019-05-23
DK3710058T3 (da) 2024-11-04
EP4487860A2 (en) 2025-01-08
AU2018366443A1 (en) 2020-06-11
JP2021502992A (ja) 2021-02-04
US20210169824A1 (en) 2021-06-10
MX2023012352A (es) 2023-10-31
GB201718862D0 (en) 2017-12-27
RU2020119390A3 (https=) 2021-12-15
KR102786614B1 (ko) 2025-03-26
JP2023168448A (ja) 2023-11-24
AU2024216397B2 (en) 2026-03-05
JP7723711B2 (ja) 2025-08-14
BR112020009508A2 (pt) 2020-10-13
EP3710058B1 (en) 2024-10-09
EP3710058A1 (en) 2020-09-23
FI3710058T3 (fi) 2024-11-11
IL274633A (en) 2020-06-30
CN111629756A (zh) 2020-09-04
GB2568471A (en) 2019-05-22
NZ764569A (en) 2024-11-29
EP4487860A3 (en) 2025-04-02
KR20200088356A (ko) 2020-07-22
RU2020119390A (ru) 2021-12-15
GB2568471B (en) 2022-04-13
CA3082433A1 (en) 2020-05-15
AU2024216397A1 (en) 2024-09-19
JP7391019B2 (ja) 2023-12-04
MX2020005147A (es) 2020-08-20

Similar Documents

Publication Publication Date Title
ES2991947T3 (es) Uso de cannabidiol además de lamotrigina para el tratamiento de las convulsiones asociadas al síndrome de Lennox-Gastaut
ES2966727T3 (es) Uso de cannabinoides en el tratamiento de la epilepsia
ES2811327T3 (es) Uso de cannabinoides en el tratamiento de convulsiones atónicas en el síndrome de Lennox-Gastaut
van Os et al. Ataxia‐telangiectasia: recommendations for multidisciplinary treatment
JP7256186B2 (ja) てんかんの治療におけるカンナビノイドの使用
ES2813431T3 (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa
ES2680656T3 (es) Uso de cannabidiol en el tratamiento de la epilepsia
WO2020152438A1 (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
BR112021010405A2 (pt) Canabidiol, e, método para tratar epilepsia associada a mutação de grin2a
Carrilero et al. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country
AU2016278088A1 (en) Use of cannabinoids in the treatment of epilepsy
TW202108133A (zh) 大麻二酚於治療結節性硬化症之用途
Alamy et al. Escitalopram in specific phobia: results of a placebo-controlled pilot trial
Merrick et al. Does melatonin have therapeutic use in tinnitus
Libal et al. Ziprasidone as a weight-neutral alternative in the treatment of self-injurious behavior in adolescent females
Lu et al. Intravenous ketamine for treatment-refractory depression in medically complex geriatric patients
Esmer Nasolacrimal system obstruction, ptosis and esotropia in a child: case report
Pusponegoro et al. Topiramate as an adjunctive therapy in children with intractable epilepsy
Montgomery Are low doses effective in obsessive compulsive disorder? evidence from placebo-controlled studies